Four-Drug attack on blood cancer shows promise in early trial
NCT ID NCT02969837
Summary
This completed Phase 2 trial tested a combination of four medications (elotuzumab, carfilzomib, lenalidomide, and dexamethasone) as the first treatment for 46 adults newly diagnosed with multiple myeloma, a cancer of plasma cells. The main goal was to see how many patients achieved a very deep response, meaning no detectable cancer cells could be found using sensitive tests after eight cycles of treatment. Researchers also tracked safety, how long patients lived without the cancer worsening, and overall survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
NorthShore University Health System
Evanston, Illinois, 60201, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109, United States
Conditions
Explore the condition pages connected to this study.